<i>In Vitro</i> Characterization of a Bivalent Anti-HER-2 Affibody with Potential for Radionuclide-Based Diagnostics
2005 · Cancer Biotherapy and Radiopharmaceuticals · 102 citations
https://doi.org/10.1089/cbr.2005.20.239
A
Ann-Charlott Steffen
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
16
Papers
426
Citations
11
h-index
12
i10-index
Ann-Charlott Steffen is an academic researcher from AstraZeneca (Sweden). The author has contributed to research in topics: Radiopharmaceutical Chemistry and Applications & Monoclonal and Polyclonal Antibodies Research & HER2/EGFR in Cancer Research. The author has an h-index of 11, co-authored 14 publications.
Papers by this author
worksAffibody-mediated tumour targeting of HER-2 expressing xenografts in mice
2006 · European Journal of Nuclear Medicine and Molecular Imaging · 65 citations
https://doi.org/10.1007/s00259-005-0012-3
Effects of HER2-Binding Affibody Molecules on Intracellular Signaling Pathways
2006 · Tumor Biology · 25 citations
https://doi.org/10.1159/000093023
Differences in radiosensitivity between three HER2 overexpressing cell lines
2008 · European Journal of Nuclear Medicine and Molecular Imaging · 22 citations
https://doi.org/10.1007/s00259-007-0713-x
Cellular uptake of radioiodine delivered by trastuzumab can be modified by the addition of epidermal growth factor
2005 · European Journal of Nuclear Medicine and Molecular Imaging · 12 citations
https://doi.org/10.1007/s00259-005-1761-8
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat